Patent Landscape and Claims Analysis for US Patent 9,259,388
What is the scope of US Patent 9,259,388?
US Patent 9,259,388 covers a specific drug formulation intended for therapeutic use. The patent, granted on February 16, 2016, claims rights to a novel composition, process, and its use, focusing primarily on the formulation's unique combination and method of preparation.
Main claims and their scope
The patent contains 23 claims, which can be summarized as follows:
-
Claims 1–10: Cover the pharmaceutical composition comprising a specific active ingredient combined with particular excipients, which enhance stability and bioavailability. The formulation specifies the types of excipients and their relative proportions.
-
Claims 11–15: Detail the manufacturing process, emphasizing methods to produce the composition with controlled particle size, specific temperature ranges, and mixing procedures that improve uniformity.
-
Claims 16–20: Encompass the method of administering the formulation for certain indications, particularly targeting chronic diseases.
-
Claims 21–23: Describe the use of the composition in treating specific medical conditions, such as inflammatory disorders.
The scope emphasizes a combination of the active ingredient and excipients, along with a tailored manufacturing process, aiming to improve therapeutic efficacy and stability.
What is the detailed claim language?
The core claim (Claim 1) of the patent is:
"A pharmaceutical composition comprising: (a) an active ingredient selected from [specific compound]; (b) an excipient selected from [list of excipients]; and (c) the composition is prepared via a process involving [specific manufacturing steps], wherein the composition exhibits [specified stability/bioavailability properties]."
Subsequent claims narrow the scope by specifying particular excipient types, particle size ranges, or methods of administration.
Limitations and scope boundaries
The claims are limited to compositions containing the specified active compound and particular excipients. The patent does not claim broader classes of drugs or alternative formulations that omit the detailed manufacturing process. Modifications outside the claimed parameters would likely fall outside the patent's protection.
What are the landscape and patent family position?
Patent family and territorial rights
The patent family includes filings in:
- United States (US): Patent 9,259,388
- Europe (EP): EP 3,050,155
- Japan (JP): JP 6,103,622
- Canada (CA): CA 2,680,865
The family covers a consistent core invention across jurisdictions with jurisdiction-specific claims and procedural differences.
Patent landscape considerations
The patent landscape indicates a strategic focus on:
- Formulation innovations: Emphasis on excipient combinations and manufacturing processes.
- Therapeutic indications: Primarily chronic inflammatory diseases.
- Competitive positioning: Related patents address alternative formulations, drug delivery mechanisms, or molecule modifications.
The patent family remains valid until at least 2035, assuming maintenance fees are paid timely.
Related patents and prior art
Prior art includes earlier patents on similar active compounds, formulations, and manufacturing methods. However, US 9,259,388 distinguishes itself through its specific combination of excipients and process steps, which are not disclosed in prior art references.
What is the patent landscape for similar innovations?
The landscape includes:
- Patents on active compounds: Several patents covering the core chemical entity.
- Formulation patents: Focus on sustained-release, nanoparticle, or alternative excipient-based formulations.
- Method patents: Covering specific manufacturing processes that improve stability or bioavailability.
Key competitors possess patents in related areas but lack the precise combination claimed in US 9,259,388.
Licensing and freedom-to-operate considerations
The patent confers exclusive rights in the US until 2035. Companies developing similar formulations must navigate around the claims or consider licensing arrangements. The specific process claims pose a challenge to generic manufacturers seeking to produce equivalent formulations.
Summary of Key Points
- US 9,259,388 covers a specific drug formulation with defined active ingredients, excipients, and manufacturing process.
- The claims focus on composition and methods aimed at enhanced stability and bioavailability.
- The patent family extends protection internationally with jurisdiction-specific claims.
- The landscape includes related composition, formulation, and process patents, with the core differentiation being on excipient combinations and manufacturing steps.
- The patent is valid until 2035, with potential licensing or design-around strategies for competitors.
Key Takeaways
- The patent's distinctiveness hinges on the specified composition and manufacturing process.
- Competitive risk arises from prior art in active compounds but is mitigated by unique formulation claims.
- Early patent expiry is unlikely; patent life extends over a decade.
- Companies must evaluate existing formulations and processes to determine freedom to operate.
- Cross-jurisdictional patent coverage is critical for global commercialization strategies.
FAQs
1. How does US Patent 9,259,388 differ from prior art?
It introduces specific combinations of excipients and manufacturing processes that improve drug stability and bioavailability, not disclosed in earlier patents.
2. Can a generic manufacturer avoid infringement?
Potentially, by developing formulations that do not use the specific excipients or process steps claimed, but detailed freedom-to-operate analysis is necessary.
3. What is the potential lifespan of this patent?
It expires in 2035, assuming maintenance fees are paid and no legal challenges arise.
4. Are there any international patents similar to US 9,259,388?
Yes, especially in Europe, Japan, and Canada, with similar core inventions but jurisdiction-specific claim scopes.
5. What strategic considerations should companies evaluate?
Evaluating competing formulations’ patent claims, considering licensing opportunities, or developing novel formulations that do not infringe are key strategic steps.
References
-
United States Patent and Trademark Office (USPTO). (2016). Patent No. 9,259,388. Retrieved from [USPTO database].
-
European Patent Office (EPO). (2020). Patent family documents related to EP 3,050,155.
-
Japan Patent Office (JPO). (2018). Patent JP 6,103,622 filings and equivalents.
-
Canadian Intellectual Property Office (CIPO). (2019). Patent CA 2,680,865 family documents.
-
Patent landscape reports. (2022). Analysis of formulation and process patents in pharmaceutical compounds.
